Search research articles
Contact Us
Filters
Showing results (111-120 of 115) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 115 results.
BMJ (Clinical Research Ed.)
|
October 23, 2024
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
Min He, Yi-Zhou Jiang, Yue Gong, et al.
Breast Cancer Research and Treatment
|
April 25, 2012
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer
Ke-Da Yu, Ying Zhou, Guang-Yu Liu, et al.
The Lancet. Oncology
|
January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Cancer Cell
|
December 5, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial
Lei Fan, Wen-Juan Zhang, Hui-Ping Li, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 115) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 115 results.
BMJ (Clinical Research Ed.)
|
October 23, 2024
Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial
Min He, Yi-Zhou Jiang, Yue Gong, et al.
Breast Cancer Research and Treatment
|
April 25, 2012
A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients' persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer
Ke-Da Yu, Ying Zhou, Guang-Yu Liu, et al.
The Lancet. Oncology
|
January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
Lei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Li Chen, Yi-Zhou Jiang, Song-Yang Wu, et al.
Cancer Cell
|
December 5, 2025
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial
Lei Fan, Wen-Juan Zhang, Hui-Ping Li, et al.
Page
of 12